Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135329 | 0.87 | PPARG (0.49) | PPARGPTGS1RXRA | |
| SCHEMBL4556106 | 0.83 | PPARG (0.48) | PPARGLMNAPTGS1RXRAAKR1B1 | |
| SCHEMBL4556253 | 0.83 | PPARG (0.48) | PPARGPTGS1RXRAAKR1B1 | |
| SCHEMBL10134840 | 0.83 | PPARG (0.51) | PPARGLMNASMN1; SMN2AKR1B1 | |
| SCHEMBL10135257 | 0.83 | PPARG (0.51) | PPARGLMNA | |
| SCHEMBL4556264 | 0.81 | PPARG (0.50) | PPARGDHODHLMNAPTGS1 | |
| SCHEMBL4556250 | 0.81 | PPARG (0.50) | PPARGHDAC1PTGS1RXRA | |
| SCHEMBL4556091 | 0.80 | PPARG (0.51) | PPARGPTGS1RXRA | |
| SCHEMBL10134925 | 0.80 | PPARG (0.53) | PPARGPTGS1RXRA | |
| SCHEMBL10134792 | 0.80 | PPARG (0.53) | PPARGPTGS1RXRATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168656-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | AANAT, FABP2, SI | PPARG 9/4885DHODH 3190/4885LMNA 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.